Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors are FDA-approved anticancer agents, validating angiogenesis inhibition.
• VEGFR inhibition alone often fails to halt tumor progression.
• The efficacy of some VEGFR inhibitors stems from targeting additional signaling pathways simultaneously.

Purpose of the Study:

• To review the crosstalk between VEGFR2 and other key signaling pathways.
• To discuss the synergistic effects of multitargeting these pathways.
• To summarize multitarget inhibitors involving VEGFR2 in clinical trials and literature.

Main Methods:

• Literature review of scientific publications, patents, and clinical trial data.
• Analysis of signaling pathway crosstalk involving VEGFR2.
• Categorization of multitarget inhibitors based on their targets.

Main Results:

• Identified crosstalk between VEGFR2 and targets including EGFR, MET, FGFR, PDGFR, c-Kit, Raf, PI3K, and HDAC.
• Demonstrated synergistic anticancer effects from simultaneous inhibition of these pathways.
• Cataloged various multitarget inhibitors targeting VEGFR2 and other pathways.

Conclusions:

• Multitargeting VEGFR2 in combination with other signaling pathways offers enhanced anticancer efficacy.
• Further development of multitarget inhibitors holds significant promise for improved cancer therapy.
• Understanding pathway crosstalk is crucial for designing effective novel cancer drugs.